- Home
- KPLT vs BOLD Comparison
KPLT vs BOLD Comparison
Compare KPLT & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPLT
- BOLD
- Stock Information
- Founded
- KPLT 2012
- BOLD 2018
- Country
- KPLT United States
- BOLD United States
- Employees
- KPLT N/A
- BOLD N/A
- Industry
- KPLT Diversified Commercial Services
- BOLD
- Sector
- KPLT Consumer Discretionary
- BOLD
- Exchange
- KPLT Nasdaq
- BOLD Nasdaq
- Market Cap
- KPLT 35.6M
- BOLD 30.3M
- IPO Year
- KPLT N/A
- BOLD 2024
- Fundamental
- Price
- KPLT $6.71
- BOLD $1.49
- Analyst Decision
- KPLT Hold
- BOLD Hold
- Analyst Count
- KPLT 2
- BOLD 1
- Target Price
- KPLT $12.00
- BOLD N/A
- AVG Volume (30 Days)
- KPLT 34.5K
- BOLD 57.3K
- Earning Date
- KPLT 05-15-2025
- BOLD 05-09-2025
- Dividend Yield
- KPLT N/A
- BOLD N/A
- EPS Growth
- KPLT N/A
- BOLD N/A
- EPS
- KPLT N/A
- BOLD N/A
- Revenue
- KPLT $247,194,000.00
- BOLD N/A
- Revenue This Year
- KPLT $20.12
- BOLD N/A
- Revenue Next Year
- KPLT $13.19
- BOLD N/A
- P/E Ratio
- KPLT N/A
- BOLD N/A
- Revenue Growth
- KPLT 11.56
- BOLD N/A
- 52 Week Low
- KPLT $5.08
- BOLD $1.06
- 52 Week High
- KPLT $23.54
- BOLD $12.26
- Technical
- Relative Strength Index (RSI)
- KPLT 33.40
- BOLD N/A
- Support Level
- KPLT $6.80
- BOLD N/A
- Resistance Level
- KPLT $7.75
- BOLD N/A
- Average True Range (ATR)
- KPLT 0.50
- BOLD 0.00
- MACD
- KPLT 0.09
- BOLD 0.00
- Stochastic Oscillator
- KPLT 31.13
- BOLD 0.00
About KPLT Katapult Holdings Inc.
Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.